CULS Conversion

RNS Number : 8764R
Alliance Pharma PLC
31 August 2010
 



For immediate release

31 August 2010

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

CULS Conversion and Additional Listing

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has received conversion requests in respect of £493,695 nominal value of the Company's 8% Convertible Unsecured Loan Stock.  Accordingly, the Company has allotted 2,350,926 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), subject to admission of the Ordinary Shares to trading on AIM.

 

Application has been made by Alliance for the 2,350,926 Ordinary Shares to be admitted to trading on AIM, and it is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 6 September 2010.

 

Following conversion and allotment, Alliance will have 234,884,298 Ordinary Shares and £5,006,055 of 8% Convertible Unsecured Loan Stock in issue.

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive


Richard Wright, Finance Director


www.alliancepharma.co.uk




Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court




Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Simon Blank


Corporate Broking: David Poutney


 

Notes to editors:

 

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

 

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

 

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFVLTEILVII
UK 100

Latest directors dealings